Standardized Assessment of Hereditary Ataxia Patients in Clinical Studies. Issue 3 (11th February 2016)

• Record Type: Journal Article
• Authors: Paap, Brigitte K.; Roeske, Sandra; Durr, Alexandra; Schöls, Ludger; Ashizawa, Tetsuo; Boesch, Sylvia; Bunn, Lisa M.; Delatycki, Martin B.; Giunti, Paola; Lehéricy, Stéphane; Mariotti, Caterina; Melegh, Jörg; Pandolfo, Massimo; Tallaksen, Chantal M.E.; Timmann, Dagmar; Tsuji, Shoji; Schulz, Jörg Bela; van de Warrenburg, Bart P.; Klockgether, Thomas
• Is Part Of: Movement disorders clinical practice. Volume 3:Issue 3(2016:Sep.)
• Page Start: 230
• Page End: 240
• Publication Date: 2016-02-11
• Subjects: ataxia -- clinical assessment -- rating scales -- quantitative performance tests -- biomaterial; Movement Disorders; Movement disorders -- Periodicals; Movement disorders; Periodicals; Periodicals; 616
• DOI: 10.1002/mdc3.12315
• Languages: English
• ISSNs: 2330-1619

Abstract

Abstract: Background: Hereditary ataxias are a heterogeneous group of degenerative diseases of the cerebellum, brainstem, and spinal cord. They may present with isolated ataxia or with additional symptoms going beyond cerebellar deficits. There are an increasing number of clinical studies with the goal to define the natural history of these disorders, develop biomarkers, and investigate therapeutic interventions. Especially, early and preclinical disease stages are currently of particular interest. Methods and Results: Evidence‐based, we review standards for sampling and storage of biomaterials, clinical and neuropsychological assessment, as well as neurophysiology and neuroimaging and recommendations for standardized assessment of ataxia patients in multicenter studies. Conclusions: DNA, RNA, serum, and, if possible, cerebrospinal fluid samples should be processed following established standards. Clinical assessment in ataxia studies must include use of a validated clinical ataxia scale. There are several validated clinical ataxia scales available. There are no instruments that were specifically designed for assessing neuropsychological and psychiatric symptoms in ataxia disorders. We provide a list of tests that may prove valuable. Quantitative performance tests have the potential to supplement clinical scales. They provide additional objective and quantitative information. Posturography and quantitative movement analysis—despite valid approaches—require standardization before implemented in multicenter studies. Standardization of neurophysiological tools, as required for multicenter interventional trials, is still lacking. Future multicenter neuroimaging studies in ataxias should implement quality assurance measures as defined by the ADNI or other consortia. MRI protocols should allow morphometric analyses.